Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Cash & Equivalents (2019 - 2026)

Opus Genetics has reported Cash & Equivalents over the past 13 years, most recently at $60.0 million for Q1 2026.

  • Quarterly Cash & Equivalents rose 43.44% to $60.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $60.0 million through Mar 2026, up 43.44% year-over-year, with the annual reading at $45.1 million for FY2025, 48.71% up from the prior year.
  • Cash & Equivalents was $60.0 million for Q1 2026 at Opus Genetics, up from $45.1 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $60.0 million in Q1 2026 and troughed at $13.9 million in Q3 2022.
  • The 5-year median for Cash & Equivalents is $40.0 million (2023), against an average of $37.1 million.
  • Year-over-year, Cash & Equivalents surged 206.03% in 2023 and then tumbled 39.96% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $42.6 million in 2022, then rose by 18.45% to $50.5 million in 2023, then tumbled by 39.96% to $30.3 million in 2024, then skyrocketed by 48.71% to $45.1 million in 2025, then surged by 32.97% to $60.0 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Cash & Equivalents are $60.0 million (Q1 2026), $45.1 million (Q4 2025), and $30.8 million (Q3 2025).